Associated researcher
Chidiebube Ugwu, MD, MPH
Clinician Scientist
Jefferson Einstein Philadelphia Hospital
Philadelphia, PA, USA
Studying why outcomes in blood cancers differ by race and ancestry: TP53 co-mutation networks in multiple myeloma (AACR Project GENIE; oral abstract, AACR 2026), ancestry-resolved mutation patterns in myelodysplastic neoplasm, and real-world evidence on tyrosine kinase inhibitor switching in chronic myeloid leukemia.
What they study
Whether differences in blood-cancer outcomes by race and ancestry are driven by the architecture of co-occurring mutations, and whether risk classifiers trained mainly in European-ancestry cohorts perform equally across ancestry groups.
How they study it
- AACR Project GENIE, MSK-IMPACT, TARGET, cBioPortal, TriNetX
- Co-occurrence and network analysis
- Propensity score matching, Cox regression, Kaplan–Meier
Selected papers
- Differences in the mutational landscape across race and sex highlight distinct TP53-associated risk in multiple myeloma Cancer Research (AACR Annual Meeting Abstracts) 2026
- Timing of Tyrosine Kinase Inhibitor Switching in Chronic Myeloid Leukemia: A Comparative Analysis of Early Versus Late Strategies Clinical Lymphoma, Myeloma & Leukemia 2026
- Targeting Inequities: Addressing Lung Cancer Care Challenges in Africa Through Drug Access, Radiotherapy, and Surgical Innovations JCO Global Oncology 2026